» Articles » PMID: 17963732

Concurrence of TDP-43, Tau and Alpha-synuclein Pathology in Brains of Alzheimer's Disease and Dementia with Lewy Bodies

Overview
Journal Brain Res
Specialty Neurology
Date 2007 Oct 30
PMID 17963732
Citations 211
Authors
Affiliations
Soon will be listed here.
Abstract

TAR-DNA-binding protein 43 (TDP-43) has been identified as a major component protein of ubiquitin-positive inclusions in brains from patients with frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis. To obtain the precise prevalence of TDP-43 pathology in neurodegenerative disorders, we examined brains from patients with tauopathies and synucleinopathies as well as FTLD-U using immunohistochemical analysis. Consequently, TDP-43-positive inclusions within neurons and oligodendroglia were found in brains from patients with Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) in addition to FTLD-U, but not with Parkinson's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration or FTDP-17. The amygdala and hippocampus that were vulnerable to tau or alpha-synuclein pathology demonstrated more severe TDP-43 pathology in AD and DLB cases than in FTLD-U cases. In contrast, in the frontal cortex and basal ganglia that were vulnerable to TDP-43 pathology in FTLD-U, TDP-43 pathology was not observed in AD and DLB cases. Thus, the neuroanatomical distribution of TDP-43 pathology in AD and DLB cases was obviously different from that in FTLD-U cases. Furthermore, a subset of TDP-43-positive inclusions co-existed with neurofibrillary tangles (NFTs) or Lewy bodies (LBs) in the same neurons. Upon double-immunofluorescent labeling analysis, TDP-43 was hardly superimposed with tau, while TDP-43 was partially superimposed with alpha-synuclein, suggesting that neither NFTs nor LBs themselves show TDP-43 immunoreactivity and that TDP-43 pathology found in this study may be related in some way to AD and LB pathology. This study will provide a more in-depth understanding of the various pathogenic pathways leading to neurodegenerative disorders.

Citing Articles

TMEM106B deficiency leads to alterations in lipid metabolism and obesity in the TDP-43 knock-in mouse model.

Yang C, Lee G, Hao L, Hu F Commun Biol. 2025; 8(1):315.

PMID: 40011708 PMC: 11865606. DOI: 10.1038/s42003-025-07752-2.


The Regulation of TDP-43 Structure and Phase Transitions: A Review.

Liu Y, Xiang J, Gong H, Yu T, Gao M, Huang Y Protein J. 2025; .

PMID: 39987392 DOI: 10.1007/s10930-025-10261-0.


Role of tau versus TDP-43 pathology on medial temporal lobe atrophy in aging and Alzheimer's disease.

Wisse L, Wuestefeld A, Murray M, Jagust W, La Joie R Alzheimers Dement. 2025; 21(2):e14582.

PMID: 39985478 PMC: 11846482. DOI: 10.1002/alz.14582.


White matter hyperintensities and TDP-43 pathology in Alzheimer's disease.

Carlos A, Weigand S, Pham N, Petersen R, Jack Jr C, Dickson D Alzheimers Dement. 2025; 21(2):ealz14516.

PMID: 39821594 PMC: 11851154. DOI: 10.1002/alz.14516.


Amygdala-predominant α-synuclein pathology is associated with exacerbated hippocampal neuron loss in Alzheimer's disease.

Gawor K, Tome S, Vandenberghe R, Van Damme P, Vandenbulcke M, Otto M Brain Commun. 2024; 6(6):fcae442.

PMID: 39659977 PMC: 11631359. DOI: 10.1093/braincomms/fcae442.